GSK-Theravance confirm 2012 US and EU filings for LAMA-LABA combo
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Theravance completed Phase III studies and confirmed that they will soon file for regulatory approval of a second inhaled chronic obstructive pulmonary disease (COPD) combination therapy.